Claris Ventures

Claris Ventures SGR SpA is a venture capital firm based in Turin, Italy, specializing in early-stage investments within the biopharma sector. Founded in 2019, the firm targets high-potential companies that emerge from the Italian research and development ecosystem. Claris Ventures aims to support innovative biopharma ventures, fostering growth and advancement in this critical field.

Pietro Puglisi

Partner

Ciro Spedaliere

Partner

Past deals in Italy

Kither Biotech

Series B in 2022
Kither Biotech s.r.l. is a pharmaceutical company based in Turin, Italy, focused on the research and development of drugs and therapies for pulmonary diseases. Founded in 2011, the company is dedicated to addressing unmet medical needs in chronic inflammatory conditions. Its main products include the KIT2014 peptide, developed internally for the treatment of cystic fibrosis, which has received Orphan Drug designation from the European Medicines Agency and is currently in the pre-clinical development phase. Additionally, Kither is advancing the development of a molecule known as CL27, aimed at treating chronic obstructive pulmonary diseases and allergic asthma, and is preparing to enter its pre-clinical phase. Through its innovative research efforts, Kither Biotech seeks to provide effective treatments for patients suffering from various respiratory diseases.

Resalis Therapeutics

Seed Round in 2021
Resalis Therapeutics treats metabolic disorders, including nash, obesity, and cancer. They provide focused on the development of oligonucleotide anti-sense therapies. Their customers contact them through address, phone, mail, and online applications.

Kither Biotech

Series A in 2019
Kither Biotech s.r.l. is a pharmaceutical company based in Turin, Italy, focused on the research and development of drugs and therapies for pulmonary diseases. Founded in 2011, the company is dedicated to addressing unmet medical needs in chronic inflammatory conditions. Its main products include the KIT2014 peptide, developed internally for the treatment of cystic fibrosis, which has received Orphan Drug designation from the European Medicines Agency and is currently in the pre-clinical development phase. Additionally, Kither is advancing the development of a molecule known as CL27, aimed at treating chronic obstructive pulmonary diseases and allergic asthma, and is preparing to enter its pre-clinical phase. Through its innovative research efforts, Kither Biotech seeks to provide effective treatments for patients suffering from various respiratory diseases.